Abstract
Perampanel (PMP) (2- [2-oxo-1-phenyl-5-pyridin-2-y1-1,2 dihydropyridin-3-y1] benzonitrile hydrate) is a novel non-competitive selective antagonist of the postsynaptic ionotropic alpha-amino-3-hydroxy-5-methyl-4-isoxazoleproprionic acid (AMPA) glutamate receptor. In this study, we compared two different methods for the quantification of perampanel in human plasma: a commercially available HPLC kit with fluorescent detector and a kit for determination of 18 different antiepileptic drugs (perampanel excluded) based on liquid chromatography-tandem mass spectrometry (LC-MS/MS) used to implement the perampanel determination. LC-MS/MS method was fully validated according to available guidelines: calibration curves were linear across perampanel concentration range of 2,5-2,800 ng/mL with correlation coefficient >0,99. Accuracy and precision results were in accordance with acceptance criteria (15%). Data collected from 95 patients, treated with perampanel as maintenance antiepileptic therapy, show a very strong correlation between the two methods. Perampanel plasma concentrations in patient samples at steady state, determined with the LC-MS/MS method, ranged from 35 to 985 ng/mL and are in line with previously reported data.
Translated title of the contribution | Determination of perampanel in plasma samples: Comparison and cross-validation between two HPLC methods utilizing two different detectors: Spectrofluorimetric and mass spectrometry |
---|---|
Original language | Italian |
Pages (from-to) | 217-224 |
Number of pages | 8 |
Journal | Biochimica Clinica |
Volume | 42 |
Issue number | 3 |
DOIs | |
Publication status | Published - Jan 1 2018 |
ASJC Scopus subject areas
- Clinical Biochemistry
- Medical Laboratory Technology
- Biochemistry, medical